prednisone has been researched along with gossypol acetic acid in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, AJ; Berry, WR; Brookes, M; de Wit, R; Eisenberger, MA; Leopold, L; Pond, GR; Sonpavde, G; Tannock, IF; Wood, BA | 1 |
| Shen, Y; Ye, D | 1 |
| Berry, WR; Brookes, M; Burke, JM; Caton, JR; Fleming, MT; Galsky, MD; Holmlund, JT; Hutson, TE; Karlov, P; Leopold, L; Matveev, V; Sonpavde, G; Wood, BA | 1 |
| Armstrong, AJ; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA | 1 |
| Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA | 1 |
| Armstrong, AJ; Chen, I; Chow-Maneval, E; Galsky, MD; Lechuga, M; Leopold, L; Michaelson, MD; Mooney, DJ; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Wang, SL; Wood, BA | 1 |
4 trial(s) available for prednisone and gossypol acetic acid
| Article | Year |
|---|---|
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Gossypol; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplastic Cells, Circulating; Orchiectomy; Placebos; Prednisone; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Treatment Outcome | 2012 |
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Prednisone; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2013 |
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Neutropenia; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Taxoids | 2012 |
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Discovery; Gossypol; Humans; Indoles; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Radiography; Retrospective Studies; Sunitinib; Survival Rate; Taxoids; Time Factors | 2014 |
2 other study(ies) available for prednisone and gossypol acetic acid
| Article | Year |
|---|---|
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Gossypol; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:363-9.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Gossypol; Humans; Male; Prednisone; Prostatic Neoplasms; Taxoids | 2012 |